Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment

被引:30
|
作者
van Geffen, Erica C. G. [1 ]
van Hulten, Rolf [1 ]
Bouvy, Marcel L. [2 ]
Egberts, Antoine C. G. [1 ]
Heerdink, Eibert R. [1 ]
机构
[1] Univ Utrecht, Fac Sci, Inst Pharmaceut Sci, Div Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands
[2] SIR Inst Pharm Practice & Policy, Leiden, Netherlands
关键词
adverse effects; nonadherence; selective serotonin-reuptake inhibitors;
D O I
10.1345/aph.1K516
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Studies have shown that up to 38% of patients who start treat ment with antidepressants fill only a single prescription at the pharmacy, I apparently not accepting treatment. OBJECTIVE: To determine characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor (SSRI) treatment. METHODS: A retrospective, study was conducted in 37 community pharmacies in the Netherlands; patients who presented a prescription from a general practitioner (GP) for a newly started SSRI treatment were selected. Nonaccepters were defined as patients who filled only one SSRI prescription; patients who received at least 3 fills of an SSRI prescription were defined as accepters. Patient characteristics were obtained from automated dispensing records and from questionnaires. Areas of evaluation included sociodemographics, disease, and treatment. Nonaccepters were asked their reasons for not filling second prescriptions. RESULTS: Of the patients who started SSRI treatment, 22.0% were nonaccepters, filling only a single prescription. Fifty-seven nonaccepters and 128 accepters were included in our analysis. Nonacceptance was more common among patients with a low level of education (OR 2.6; 95% CI 1.1 to 5.9) and in patients who reported nonspecific symptoms like fatigue, stress, and restlessness as the reason for SSRI use (OR 2.7; 95% CI 1.4 to 5.5). Of the nonaccepters, 29.8% (n = 17) did not start SSRI use, and 70.2% (n = 40) discontinued SSRI use within 2 weeks. Fear of adverse effects and the actual occurrence of adverse effects were main reasons for not accepting SSRI treatment. Of the nonaccepters, 55.0% discontinued treatment without informing their GPs. CONCLUSIONS: Acceptance of SSRI treatment is a decisive moment in a patient's adherence to treatment initiated by his or her GP and deserves more attention; GPs and pharmacists should address treatment issues, especially in groups at risk for nonacceptance.
引用
收藏
页码:218 / 225
页数:8
相关论文
共 50 条
  • [21] Use of selective serotonin-reuptake inhibitors in the treatment of depression in adults with HIV
    Caballero, J
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 2005, 39 (01) : 141 - 145
  • [22] Selective serotonin-reuptake inhibitors in pregnancy and lactation
    Baum, AL
    Misri, S
    HARVARD REVIEW OF PSYCHIATRY, 1996, 4 (03) : 117 - 125
  • [23] Effect of High Selective Serotonin-Reuptake Inhibitor Doses on the Development and Treatment of Sarcoid-Like Reaction
    Al-Ghamdi, Badr Rashed
    CASE REPORTS IN MEDICINE, 2020, 2020
  • [24] Patients' Perceptions of Information Received at the Start of Selective Serotonin-Reuptake Inhibitor Treatment: Implications for Community Pharmacy
    van Geffen, Erica C. G.
    Kruijtbosch, Martine
    Egberts, Antoine C. G.
    Heerdink, Eibert R.
    van Hulten, Rolf
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (04) : 642 - 649
  • [25] Remission of chronic severe selective serotonin-reuptake inhibitor/selective norepinephrine-reuptake inhibitor refractory depression following adjunctive aripiprazole
    Sokolski, Kenneth N.
    Gripeos, Dimitrios
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (09) : 1348 - 1349
  • [26] Selective Serotonin Reuptake Inhibitor Treatment and Depression Are Associated with Poststroke Mortality
    Ried, L. Douglas
    Jia, Huanguang
    Feng, Hua
    Cameon, Randi
    Wang, Xinping
    Tueth, Michael
    Wu, Samuel S.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (7-8) : 888 - 897
  • [27] Selective serotonin-reuptake inhibitors and chemoprevention of colorectal cancer
    Sorensen, HT
    LANCET ONCOLOGY, 2006, 7 (04): : 277 - 279
  • [28] Selective serotonin-reuptake inhibitors and movement disorders.
    Sobel, HR
    Dias, C
    Medina-Walpole, AM
    Katz, PR
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2003, 51 (04) : S50 - S50
  • [29] Citalopram versus other selective serotonin-reuptake inhibitors
    Thomas, KV
    Holimon, TD
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 (21) : 2242 - 2244
  • [30] Adverse event reporting with selective serotonin-reuptake inhibitors
    Hartnell, NR
    Wilson, JP
    Patel, NC
    Crismon, ML
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (10) : 1387 - 1391